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Abstract:
Introduction
Tc-Duramycin is a peptide-based molecular probe that binds
specifically to phosphatidylethanolamine (PE). The goal was to characterize
the kinetics of molecular interactions between 99mTc-Duramycin and the target
tissue.
99m

Methods
High level of accessible PE is induced in cardiac tissues by myocardial
ischemia (30 min) and reperfusion (120 min) in Sprague Dawley rats. Target
binding and biodistribution of 99mTc-duramycin was captured using SPECT/CT.
To quantify the binding kinetics, the presence of radioactivity in ischemic
versus normal cardiac tissues was measured by gamma counting at 3, 10, 20,
60 and 180 min after injection. A partially inactivated form of 99mTcDuramycin was analyzed in the same fashion. A compartment model was
developed to quantify the uptake kinetics of 99mTc-Duramycin in normal and
ischemic myocardial tissue.
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Results
Tc-duramycin binds avidly to the damaged tissue with a high
target-to-background radio. Compartment modeling shows that accessibility
of binding sites in myocardial tissue to 99mTc-Duramycin is not a limiting
factor and the rate constant of target binding in the target tissue is at 2.2
ml/nmol/min/g. The number of available binding sites for 99mTc-Duramycin in
ischemic myocardium was estimated at 0.14 nmol/g. Covalent modification of
D15 resulted in a 9 fold reduction in binding affinity.
99m

Conclusion
Tc-Duramycin accumulates avidly in target tissues in a PEdependent fashion. Model results reflect an efficient uptake mechanism,
consistent with the low molecular weight of the radiopharmaceutical and the
relatively high density of available binding sites. These data help better define
the imaging utilities of 99mTc-Duramycin as a novel PE-binding agent.
99m

Keywords:

99m

Tc-Duramycin, phosphatidylethanolamine, imaging agent.

INTRODUCTION
The asymmetrical distribution of phospholipids in cellular
membranes is of fundamental importance [1,2]. The status of this
asymmetry has been increasingly recognized as a molecular marker
for normality and diseases.
A number of imaging agents have been described in pursuit of
targeted imaging capabilities for membrane phospholipids. Annexin V,
the C2A domain of Synaptotagmin I, and the C2 domain of Lactadherin
are examples of protein-based phosphatidylserine (PS)-binding
imaging agents [3–5]. Structural features of these agents can be
generalized as including 1) a binding site designed to accommodate
the head group of a target phospholipid, and 2) exposed hydrophobic
side chains at the vicinity of the binding site for interacting with the
core of the phospholipid bilayer. The first feature enables the
recognition of phospholipid head groups, while the second provides an
anchoring mechanism that drives toward membrane binding.
Duramycin, which is a lantibiotic peptide, also meets the
structural criteria for targeting phospholipid membranes, but it binds
specifically to phosphatidylethanolamine (PE) [6]. Apart from
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apoptosis, emerging evidence indicates that the dynamics of
membrane PE is involved in a number of biological functions, including
cytokinesis and possibly hemostasis [7,8]. Thus, the unique binding
activity of Duramycin adds to the repertoire of membrane-binding
agents by enabling a new perspective in investigating the fundamental
biology of membrane phospholipid distribution. Initial studies on 99mTclabeled Duramycin indicate that the agent has good uptake in target
tissues with rapid renal clearance and a low general background in
vivo [9]. These properties are consistent with the structural features of
Duramycin. More specifically, Duramycin is one of the smallest
possible polypeptide (19 amino acids) that has a defined 3dimensional binding structure [6,10]. The peptide is extensively crosslinked by intramolecular covalent bridges, thus exhibiting relatively
high in vivo stability. The agent has binding activities comparable to
large proteins, yet with peptide-like pharmacokinetics. The
combination of these factors makes Duramycin an attractive candidate
as an imaging agent for studying phospholipid distribution in the living
system.
In light of these initial findings, the objective of the current
study was to understand how 99mTc-Duramycin behaves in the target
tissue, by quantifying the kinetics of interactions between 99mTcDuramycin and its molecular targets in vivo. We hypothesize that the
combination of high target density and fast probe diffusion in tissue
will lead to more efficient uptake, thus superior imaging properties.
The in vivo experiment will be carried using a rat model of
myocardial ischemia and reperfusion. It has been demonstrated that
both PE and PS are externalized in dead and dying mammalian cells
[11]. Additionally, extensive pathological data have documented that
prolonged ischemia followed by reperfusion causes destabilization of
sarcolemmal structure. Severe ischemic insult eventually leads to
compromised phospholipid membrane integrity, rendering high levels
of phosphatidylethanolamine accessible to extracellular agents [12–
14]. The advantages of using this animal model include a relatively
defined perfusion profile, high target density in the ischemically
damaged myocardium versus a low background in the viable
myocardium. The quantitative dynamic data acquired using this
system, in turn, will help better define the utilities of 99mTc-Duramycin
as a novel radiopharmaceutical. Importantly, this type of data will be
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instrumental in gauging the incremental values of an imaging agent
compared with past and future generation agents for similar purposes.

MATERIALS AND METHODS
Radiolabeling of Duramycin
Duramycin and its partially inactivated form, DuramycinI, were
covalently modified with HYNIC. The molecular weight of the HYNICmodified Duramycin was confirmed using Matrix-assisted laser
desorption/ionization (MALDI) mass spectrometry. The
radiopharmaceutical was prepared using a single-step kit formulation.
The partially inactivated form of 99mTc-Duramycin was prepared in the
same fashion. Quality control steps, including stability tests, were
carried out as described before [11]. The radiopharmaceutical dose
consistently has a radiochemical purity at 95% or greater, and is
stable without significant presence of dissociated radioactivity.

Rat Model of Myocardial Ischemia and Reperfusion
The animal protocol was approved by the Institutional Animal
Care and Use Committee under the NIH guideline. Male SpragueDawley rats were anesthetized with sodium pentobarbital (50 mg/kg)
intraperitoneally. After tracheal intubation, respiration was maintained
using a rodent ventilator. An incision was made between the 4th
intercostal space to expose the heart. After opening the pericardium,
the proximal left anterior descending coronary artery (LAD) was
occluded for 30 minutes using a 6.0 suture at about 1 mm below the
left atrial appendage. For sham operation, the suture was passed
underneath the LAD without ligation. The presence of acute
ischemia/reperfusion was confirmed by the pale appearance in the
area-at-risk region and changes in ECG profiles. After reperfusion the
chest wall was closed and ventilation was maintained until the rat
could regain spontaneous respiration. The loose suture was left in
place for area-at-risk staining.

SPECT studies
Static SPECT data were acquired at 40 min after radiotracer
injection (37 MBq, i.v.) on a Triumph microSPECT/microCT scanner
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(GE Healthcare, Waukesha, WI) equipped with a quad-detector SPECT
system. The imaging parameters include multi-pinhole collimators for
rat, 1.0 mm spatial resolution, 1100 counts per MBq sensitivity, 15%
energy window centering at 140 keV, 50 × 50 mm trans-axial field of
view, 170 mm axial field of view, 72 projections at 10 seconds each.
SPECT acquisition was followed by CT, using the same field of view.
The imaging data were reconstructed using the inbuilt software.

Spatial and Temporal uptake of 99mTc-Duramycin and
its partially inactivated form in the area-at-risk
To investigate the temporal uptake kinetics of 99mTc-Duramycin
in the area-at-risk, 20 rats were enrolled to simulate acute myocardial
infarction with 30 min coronary occlusion as described above. At 2 hr
after reperfusion the radiotracer was injected intravenously (0.1 mCi).
One group of 4 rats was sacrificed for measurements at each of the
following time points: 3, 10, 20, 60 and 180 min after injection.
Immediately before sacrifice, a second thoracotomy was performed to
expose the heart. The LAD was re-occluded at the same location by
tightening the suture in place. Two mls of Evans Blue dye (2% w/v in
PBS, pH 7.4) was infused into the tail vein. Area-at-risk was delineated
by an absence of blue dye uptake, while the normally perfused
myocardium is stained dark blue. The heart was quickly excised, and
the dissected tissues were separately weighed and collected in sample
tubes for gamma counting as follows: normal (blue), ischemic infarct
(unstained). Three aliquots of 99mTc-Duramycin solution were taken at
5 ml each and were measured for radioactivity as standards for the
calculation of total injected dosage (ID). The radioactivity uptake of
99m
Tc-Duramycin at each time point after injection was presented as
percentage of injected dosage per gram (%ID/g) with standard
deviation. The above studies were repeated in another group of 20
rats using the partially inactivated form of Duramycin.

Compartmental model
We modified a previously developed compartmental model for
quantitative interpretation of the uptake kinetics of active and partially
inactivated 9mTc-Duramycin in normal and infarct myocardium [17].
The model (Figure 1) consists a vascular region with volume V1 (ml)
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representing the coronary circulation. For MI, the model allows 99mTcDuramycin to participate in specific binding, where B is the amount
(nmol) of free binding sited that are readily accessible to 99mTcDuramycin at time t, and ks (ml nmol−1 min−1) is the association rate
constant of 99mTc-Duramycin interaction with binding sites. For normal
myocardial tissue, the model assumes that the binding sites are not
accessible to 99mTc-Duramycin from the coronary circulation.

Figure 1

Compartmental model for the disposition of

99mTc-Duramycin

in ischemic

cardiac tissue (a.) and viable tissue (b.). [C1](t) is the probe concentration in the MI
vascular region at time t; C2(t) is the amount of bound probe at time t. B is the
amount of free receptors or binding sites at time t that is readily accessible for probe
within the MI blood region; ks is the probe-receptor association rate constant; F is the
blood flow of the coronary circulation and [Cin](t) is the input probe concentration for
the coronary circulation.

Using mass balance and mass action, the temporal variations in
the activities of free and bound 99mTc-Duramycin in V1 are described by
Equations (1–2)
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where [C1](t) is the probe concentration (µM) in the MI vascular space
at time t (t = 0 is probe injection time); C2(t) is the amount (nmol) of
probe sequestered in the MI region via specific binding at time t; F is
the blood flow of the coronary circulation (~ 1 ml min−1 g−1); [Cin](t) is
the input probe concentration for the coronary circulation, which was
estimated from previously measured 99mTc-Duramycin plasma
clearance profile as described below; and Bmax is the total amount
(nmol) of readily accessible receptors or binding sites. The above
equations are subject to the following initial (t = 0) conditions: [C1](t
) = 0 µM, and C2(t) = 0 nmol. The total activated probe concentration
at a given time t, Ctotal(t) in %ID g−1 of tissue, in the system is

where ID (g) is the injected dose (~10 µg per 300 g rat); m (g)
is the total mass of at-risk tissue (average 201 mg), and MW is the
molecular weight of the radiopharmaceutical (3035 g mol −1).
The model assumes that the partially inactivated form of 99mTcDuramycin differs from the active form only in its affinity for the
binding sites. Thus, the active and partially inactivated forms have the
same Bmax, V1 and [Cin](t), but different ks values.
The governing differential equations for the disposition of 99mTcDuramycin in normal myocardium reduce to Equation (1) with Bmax set
to zero. Thus, for normal myocardium, Equation (3) reduces to:
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Statistical comparisons were carried out using t-test or paired ttest, with P < 0.05 as the criterion for statistical significance.

RESULTS
Whole-body imaging
Whole-body SPECT images are shown in Figure 2. The high focal
uptake of radioactivity is clearly seen in the ischemic myocardium in
the tomographic images, which is made more conspicuous because of
a lack of significant hepatic background. This is accompanied with a
low systemic background and rapid renal/urinary clearance.
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Figure 2

Representative SPECT/CT images of

99mTc-Duramycin

uptake in

ischemically damaged cardiac tissue in vivo. The CT, SPECT and SPECT/CT fusion
images are shown in the left, middle and right columns, respectively. Radioactivity
uptake in the left ventricular free wall is highlighted with an arrow in the tomographic
images.

Spatial and Temporal uptake of
area-at-risk

99m

Tc-Duramycin in the

The uptake kinetics of 99mTc-Duramycin in the area-at-risk was
characterized by measuring the level of radioactivity at different time
points after injection and is summarized in Figure 3. Quantitative
uptake data from dissected heart tissues of the infarct, and normal
myocardium at 3, 10, 20, 60 and 180 min after tracer injection are
presented. After injection the radioactivity uptake in the infarcted
myocardium rapidly rose to 1.66 ± 1.18 (SD) %ID/g within 3 min, and
approached a plateau by 10 min at 3.66 ± 0.76 %ID/g. The
radioactivity uptake in the normal myocardium was low, reflecting the
residual blood pool signal. According to the measurements using
dissected heart tissues, at 60 min after injection, the average infarctto-normal ratio was ~29. The radiotracer was sequestered in the
irreversibly damaged myocardium, which is consistent with the high
binding affinity and specificity of Duramycin-PE interactions. Chemical
modification of a single amino acid (D15) resulted in a marked
reduction in probe uptake (Figure 3).
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Figure 3

Kinetic analysis. Radioactivity uptake of the active and partially

99mTc-Duramycin,

inactivated
in terms of %ID/g, in ischemic and normal myocardium
at 3, 10, 20, 60, and 180 min after intravenous injection. Values are mean ± SD. N =
4 for active and partially inactivated 99mTc-Duramycin at each of the time points. Solid
lines are model fits. * Uptake of 99mTc-Duramycin in area-at-risk is significantly
different from that for the partially inactivated 99mTc-Duramycin at the same time point
(P < 0.05). # Uptake of partially inactivated 99mTc-Duramycin in area-at-risk is
significantly different from its uptake in viable tissue at the same time (P < 0.05)

Kinetic analysis
The model parameters are V1 (ml), the volume of the vascular
region; Bmax (nmol) the total amount of specific receptors or binding
sites accessible to 99mTc-Duramycin in MI tissue; and ks (ml nmol −1
min−1), the probe-receptor association rate constant. Estimation of
these parameters was carried out as follows. First, Cb(t), as %ID, was
determined by fitting Equation (5) to previously measured 99mTcDuramycin plasma clearance profile as a fraction of injected dose.
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where a, b and (100 − a − b) are the amplitudes of the three
exponentials with rate constants α1 α2, and α3, respectively. The
estimated values of the amplitudes a and b were 19.0 and 19.1 %ID,
respectively. The estimated values of the rates constant α1, α2 and α3
were 0.42, 0.02 and 0.42 min−1, respectively, and the estimated halflife of the probe was 2.2 min.
Knowing Cb(t), the input probe concentration for the coronary
circulation, [Cin](t) (in µM), was determined using

where Vin (ml) is the rat blood volume (~ 7% of total body
weight).
Knowing [Cin](t), V1 (ml) was estimated by solving Equation (1)
with Bmax = 0, and fitting Equation (4) to active or partially
inactivated 99mTc-Duramycin activity versus time uptake data in
normal myocardium (Figure 1). The estimated values of V1 from the
active or partially inactivated 99mTc-Duramycin uptake data were
virtually the same (Table 1). Knowing V1, the remaining parameters
namely, Bmax, and the association rate constant (ks) for the active
(ksa ) and partially inactivated (ksi) 99mTc-Duramycin were then
estimated by solving Equations (1–2) with ks set to ksa or ksi, and
fitting the resulting solutions of Equation (5) simultaneously to the
active and partially inactive 99mTc-Duramycin uptake data in MI (Figure
3). The solid lines in Figure 3 demonstrate the ability of the model to
fit the data.
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Table 1

Estimated values and asymptotic confidence intervals of kinetic model

parameters for

99mTc-Duramycin

ksa: binding rate constant for

in area-at-risk

99mTc-Duramycin.

ksi: binding rate constant for the partially inactivated

99mTc-Duramycin.

Table 1 shows the estimated values of the model parameters
and measures of precision of these estimates, namely asymptotic 95%
confidence intervals.

DISCUSSION
Significant findings from the current investigation include the
follows: i) 99mTc-Duramycin has rapid uptake in the target tissue,
presumably in a PE-dependent manner. Once bound, there is minimal
washout over extended period of time. ii) The binding kinetics of 99mTcDuramycin is quantitatively analyzed, where these values allow an indepth understanding of the strength and limitations of this imaging
agent. An added benefit is that the availability of quantitative kinetic
data enables an assessment of incremental values and for guiding the
development of future generation agents. The current findings are
discussed in more details as follows.
Cognate interactions between the probe and binding target are
dependent on the accessibility of these targets to probe from the
vascular region. Smaller probes tend to have a greater tissue
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permeability, which leads to a more efficient target access. To date, a
phospholipid-binding agent other than 99mTc-Duramycin with
established quantitative kinetic data is 99mTc-C2A-GST. Comparatively,
probe’s tissue permeability was a limiting factor for 99mTc-C2A-GST,
but not for 99mTc-Duramycin, in part due to its much lower molecular
weight.
Using kinetic analysis, we were able to estimate the binding rate
constant for 99mTc-Duramycin in the target tissue. This value reflects
the binding affinity of the agent in the actual tissue settings. The
availability of the in vivo binding rate constant enables comparative
studies that are free from extrapolations based on binding constants
obtained from in vitro binding assays. According to the current study,
the binding rate constant (ks) for 99mTc-Duramycin is comparable than
that of 99mTc-C2A-GST (Table 2) [13]. Quantitative analysis indicates
that covalent modification of D15, which forms a portion of Duramycin
binding pocket, resulted in a substantial decrease in binding rate
constant. This is indicative that the uptake of 99mTc-Duramycin is
indeed PE dependent.

Table 2

Comparison of values of model parameters descriptive of the uptake of

99mTc-Duramycin

and

99mTc-C2A-GST

in area-at-risk

V1 and Bmax are normalized to mass of at-risk tissue. ksa is binding rate constant for
99mTc-Duramycin.

In terms of total binding capacity (Bmax), this is a parameter that
is intrinsic to the target tissue, and is a measure of the available
binding sites for a given probe. By comparing the kinetics between
99m
Tc-Duramycin and 99mTc-C2A-GST, two membrane-binding agents
that differ from structural properties to binding targets, it provides a
unique opportunity to look at the total binding capacity from two
independent angles. According to the kinetic analysis results, the Bmax
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(nmol/g) for 99mTc-Duramycin, which is the density of available PE, is
about 3-fold greater than that of 99mTc-C2A-GST (Table 2), which is
the density of available PS [13]. This outcome is consistent with the
published values of PE/PS ratio from cellular membranes [14]. It is
indicative that the molecular targets, PE and PS, are constituents of a
single pool of membrane phospholipids exposed in dead and dying
cells. A significant point of the current study, therefore, is that the
underlying pathophysiology is a constant beyond the variability of
different imaging agents or their targets.
The ~3-fold difference in the number of available binding sites
for
Tc-Duramycin as compared to 99mTc-C2A-GST resulted in only
~50% increase in the uptake of 99mTc-Duramycin in MI at steady state
as compared to 99mTc-C2A-GST [13]. This result is in part due to the
faster blood clearance rate of 99mTc-C2A-GST as compared to 99mTcC2A-GST (Table 2). This stresses the importance of the above kinetic
modeling approach for the quantitative interpretation of 99mTcDuramycin kinetic data since the 3-fold difference in the number of
available binding sites cannot be predicted directly from the kinetic
data without accounting for the contributions of the other factors that
determine the uptake kinetics of 99mTc-Duramycin in MI, including
blood clearance rate, probe tissue permeability, and probe-target
binding rate constant.
99m

In terms of potential impact on patient care, current clinical
radiotracers are valuable in providing perfusion, functional and
metabolic information on target tissues, such as the heart; however,
there lacks a positive imaging agent for detecting active cell death in
degenerative diseases. A targeted radiotracer that binds externalized
phospholipids as a surrogate marker for cell death will aid the early
detection of tissue injury and the monitoring of the efficacy of
therapeutic interventions.
Overall, in a quantitative approach, we have characterized the in
vivo behaviors of 99mTc-Duramycin in the target tissue. The relatively
high target-to-background ratio is due to a combination of the
following factors: enhanced tissue permeability, site-directed
radiolabeling, prompt blood clearance, and a greater target density.
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